PER977
PER977
PER977 (also known as Ciraparantag) is a synthetic, small molecule anticoagulant reversal agent. It is designed to reverse the anticoagulant effects of direct and indirect anticoagulants.
Pronunciation
PER977 is pronounced as P-E-R-Nine-Seven-Seven.
Etymology
The name PER977 is derived from the initial development code assigned to the molecule during its research phase. The 'PER' prefix is an abbreviation of Perosphere, the pharmaceutical company that initially developed the drug, and '977' is a unique identifier.
Mechanism of Action
PER977 works by binding to anticoagulants in the blood and reducing their activity, thereby reversing their anticoagulant effects. It has been shown to reverse the effects of a wide range of anticoagulants, including direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, and edoxaban, as well as indirect anticoagulants such as heparin and fondaparinux.
Related Terms
- Anticoagulant: A drug that helps prevent blood clots from forming.
- Dabigatran: A direct oral anticoagulant (DOAC) used to treat and prevent blood clots.
- Rivaroxaban: A DOAC used to treat and prevent blood clots.
- Apixaban: A DOAC used to treat and prevent blood clots.
- Edoxaban: A DOAC used to treat and prevent blood clots.
- Heparin: An indirect anticoagulant used to treat and prevent blood clots.
- Fondaparinux: An indirect anticoagulant used to treat and prevent blood clots.
External links
- Medical encyclopedia article on PER977
- Wikipedia's article - PER977
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski